

TABLE A.6.—ANALYSIS OF CARDIOVASCULAR DEATHS IN THE UGDP TRIALS USING THE LOGISTIC MODEL

	df	Likelihood ratio X^2	P
Both sexes:			
Constant	1	706.03	.001
Time	1	23.56	.001
Treatments	3	10.46	.02
Treatments adjusted for time	3	10.68	.02
Demographic variables and risk factors	14	95.87	.001
Treatments adjusted for demographic variables	3	11.55	.01
Treatments adjusted for demographic variables and time	3	12.30	.01
Clinics adjusted for treatments and time	11	27.68	.01
Treatments adjusted for clinics and time	3	10.91	.02
Treatments adjusted for demographic variables, clinics, and time	3	11.98	.02
Clinics adjusted for demographic variables, time, and treatments	11	14.33	.01
Clinics adjusted for demographic variables and treatments	11	30.53	.01
Demographic variables adjusted for clinics, time, and treatments	14	82.56	.001
Tolbutamide treatments adjusted for demographic variables, clinics, and time	1	11.66	.001
Other treatments adjusted for demographic variables, clinic, time, and tolbutamide treatment	2	0.32	-----
Subset of demographic variables adjusted for treatment and time ¹	6	83.05	.001
Other demographic variables and clinics	19	27.19	-----
Treatments adjusted for subset of demographic variables and time	3	12.31	.01
Tolbutamide treatment adjusted for subset of demographic variables, time, and insulin treatments (tolbutamide vs. placebo)	1	8.49	.01
Insulin treatments adjusted for subset of demographic variables, time, and tolbutamide treatment (insulin vs. placebo)	2	0.17	-----
Tolbutamide treatment adjusted for subset of demographic variables and time (tolbutamide vs. other treatments)	1	12.14	-----
Insulin treatments adjusted for subset of demographic variables and time (insulin vs. other treatments)	2	3.82	-----
Men:			
Constant	1	159.53	.001
Demographic variables and time	6	35.45	.001
Treatments adjusted for variables and time	3	5.07	-----
Tolbutamide treatment adjusted for insulin treatments, demographic variables, and time (tolbutamide vs. placebo)	1	0.35	-----
Insulin treatments adjusted for demographic variables time and tolbutamide treatment (insulin vs. placebo)	2	2.52	-----
Tolbutamide treatment adjusted for demographic variables and time (tolbutamide vs. other treatments)	1	2.56	-----
Insulin treatments adjusted for demographic variables and time (insulin vs. other treatments)	2	4.72	-----
Women:			
Constant	1	551.79	.001
Demographic variables and time	6	67.66	-----
Treatments adjusted for variables and time	3	12.23	-----
Tolbutamide treatment adjusted for insulin treatments, demographic variables, and time (tolbutamide vs. placebo)	1	11.70	.01
Insulin treatments adjusted for demographic variables, time, and tolbutamide treatment (insulin vs. placebo)	2	2.52	-----
Tolbutamide treatment adjusted for demographic variables and time (tolbutamide vs. other treatments)	1	9.06	.01
Insulin treatments adjusted for variables and time (insulin vs. other treatments)	2	0.53	-----

¹See table A.5.